Jessica Rendall is a reporter with experience covering a variety of health and wellness topics, including chronic disease, infectious disease, telemedicine, mental health and health technology. Emily ...

On April 1, the U.S. Food and Drug Administration (FDA) clarified its policies on compounded drugs, including compounded versions of GLP-1 products. Compounders are permitted to produce copies of ...

The FDA has clarified its policies regarding GLP-1s, stating that pharmacies must stop compounding GLP-1 drugs once branded versions are removed from the agency’s shortage list, signaling a narrower ...

As GLP-1 medications grow in popularity not just for treating diabetes but also for weight loss, some people are turning to alternatives that health experts warn may carry risks. Amelia Baker, a ...

Drugmaker Eli Lilly says some copycat versions of its GLP-1 medications pose unique safety concerns — here’s what you need to know. A new study funded by Eli Lilly found that mixing compounded ...

Eli Lilly (LLY) has issued a public warning about potential safety risks associated with compounded tirzepatide mixed with vitamin B12. Lilly tested compounded products and found “significant levels ...

Though it’s hard to say exactly what the future holds for mass GLP-1 compounding, the pressure is mounting from multiple angles in the U.S. as drugmakers and the FDA alike seek to crack down on the ...

WASHINGTON, March 12 (Reuters) - Compounded weight-loss drugs that contain vitamin B12 and the ‌main ingredient in Eli Lilly's (LLY.N), opens new tab Zepbound could present health risks to consumers ...

The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. In its latest offensive, the agency has unleashed a fresh set of 30 warning letters targeting ...

Having targeted Hims & Hers last year, the FDA has issued warnings to more telehealth companies over their promotion of GLP-1 drugs used to treat diabetes and obesity. In one case, compounded products ...

The Food and Drug Administration (FDA) on Tuesday sent 30 telehealth companies warning letters about their “illegal” sales of compounded GLP-1s, building off increasing pressure to tamp down on the ...

As GLP-1s remain popular across the U.S., the Food and Drug Administration says it’s now prepared to rein in a fast-growing corner of the market: compounding pharmacies and telehealth companies that ...